Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas

• Conditions: Benign Neoplasm of Salivary Gland; Malignant Neoplasm of Salivary Gland

• Registration Number: NCT03687294
• Lead Sponsor: Cairo University

Brief Summary

in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-09-26
• Study First Submitted QC: 2018-09-26
• Study First Posted: 2018-09-27
• Study Start: 2019-01-12
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-19
• Last Update Posted: 2020-07-21
• Primary Completion: 2021-09
• Study Completion: 2021-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

.

• Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I
• Benign tumors will be recruited in group II.

Exclusion Criteria

• Subjects taking any drugs inducing any changes that could affect the salivary glands.
• Pregnant females.
• Subjects having any allergies, infectious or autoimmune diseases.
• Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas	two years	Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas.

Trial Locations

Locations (1)

National Cancer Institute; 🇪🇬 Cairo, Egypt